Breast cancer (BC) is the leading cause of cancer-related mortality among women, with early BC (EBC) comprising most cases. Advancements in neo(adjuvant) therapies have significantly improved outcomes, although they are often associated with cancer treatment-induced bone loss, which increases the risk of fractures and negatively impacts quality of life.
This study aims to unravel the relationship between apolipoprotein C1 (APOC1) levels, prognostic nutritional index (PNI), and clinicopathological characteristics in patients with diffuse large B-cell lymphoma (DLBCL) and their prognostic predictive value.
This study retrospectively analyzed clinical data from 55 DLBCL patients and 50 healthy screening volunteers. APOC1 levels and the PNI were compared between groups, along with their association with DLBCL’s clinicopathological features.
To assess the value of biologically enriched Normal Tissue Complication Probability (NTCP) models integrating clinical, dosimetric, and biological markers, specifically the RadioDtect© assay based on phosphorylated ATM (Ataxia-Telangiectasia Mutated, pATM) quantification.
We considered 67 patients with head-and-neck cancer receiving curative-intent radiotherapy. We developed logistic NTCP models for severe acute/late toxicities (grade ⩾3) using (i) the pATM-based RadioDtect test, (ii) clinical-dosimetric variables, and (iii) a combined model.